1. Pink Sheet
  2. >>Compliance
  3. >>Marketing & Advertising

Biogen Agrees To One Of Largest FCA Settlements Without DOJ Intervention

 
• By Brenda Sandburg

Company to pay $900m to resolve claims it paid kickbacks to physicians to induce them to prescribe its multiple sclerosis drugs. Whistleblower sought damages based on the number of prescriptions written after a healthcare provider received a kickback from Biogen.

Whistleblower
Biogen agrees to settle whistleblower suit alleging it provided kickbacks to get physicians to prescribe its multiple sclerosis drugs • Source: Shutterstock

While the US Department of Justice decided not to intervene in a whistleblower False Claims Act complaint against Biogen, Inc., it is reaping one of the biggest payouts in an FCA settlement in recent years. Biogen agreed to pay $900m to resolve claims that it paid kickbacks to physicians to encourage them to prescribe its three multiple sclerosis drugs.

The settlement, announced on 20 July, shows that companies are vulnerable even when the government opts not to pursue a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Marketing & Advertising

More from Compliance

PBM Investigation, Enforcement Action ‘Critical Priorities’ At FTC, Chair Says

 
• By Cathy Kelly

The new FTC chair addressed concerns that staffing cuts will undermine the commission’s commitment to pharmacy benefit manager oversight.

US FDA’s Familiar Drug Pricing To-Do List

 
• By Michael McCaughan

President Trump’s new Executive Order on drug pricing reprises several policy themes from his first administration, including giving the FDA many tasks intended to increase competition in the marketplace.

Pharma DTC Ad Tax Break Targeted By US HHS, Congress

 
• By Derrick Gingery

Health and Human Services Secretary Robert F. Kennedy Jr. said a policy that would remove the tax write-off for pharma advertising expenses would be coming in a few weeks.